Aligos Therapeutics, Inc.
No enriched coverage for $ALGS in the last 7 days.
No SEC Form 4 filings for $ALGS in the last 30 days.
See all $ALGS insider activity →Aligos Therapeutics (ALGS) will present five abstracts at AASLD 2026, covering HBV and HDV programs. Key data includes pevifoscorvir sodium's immune-modulatory effects and long-term treatment results. The company also reported cash reserves of $30.4M (excluding a $25M upfront payment) and expects funding into Q4 2026. ALGS stock closed at $5.40, down 2.53%.
Analysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.
Novo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
Recent ALGS coverage spans mergers & acquisitions, technology and financial news.
The upcoming conference presentations introduce new data that could affect investor sentiment, but no results are disclosed yet.
Upgrade may spark buying interest.
Sharp sell‑off suggests adverse news or missed expectations.
The lease extension secures the company's headquarters location but adds incremental rent costs and a termination fee, modestly affecting cash flow.
The pre‑open surge suggests short‑term buying pressure but lacks a fresh catalyst.
AlphAI scores every news story that mentions ALGS with an AI model for sentiment and relevance, and aggregates insider trades from Aligos Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aligos Therapeutics (ALGS) will present five abstracts at AASLD 2026, covering HBV and HDV programs. Key data includes pevifoscorvir sodium's immune-modulatory effects and long-term treatment results. The company also reported cash reserves of $30.4M (excluding a $25M upfront payment) and expects funding into Q4 2026. ALGS stock closed at $5.40, down 2.53%.
1 min readAnalysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.
3 min readNovo Nordisk (NVO) shares fell 4.8% to $41.15 in pre-market trading after Phase 3 trial results. Other stocks moving lower include Aligos Therapeutics (ALGS) down 15.1%, Telix Pharmaceuticals (TLX) down 7.9%, and Li Auto (LI) down 3.5%.
2 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 10, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into the First Amendment to Lease (the “First Amendment”) with Britannia Biotech Gateway Limited Partnership (the “Landlord”), to amend the Lease, dated
1 min readAligos Therapeutics (ALGS) stock rose 7.6% in pre-market trading to $6.55, despite a broader market decline. The rally follows recent operational milestones, better-than-expected Q2 2026 earnings, and a completed Phase 2 study enrollment for its hepatitis B treatment. The company's balance sheet was strengthened by a licensing deal. The stock remains below its 52-week high of $13.69.
1 min readAligos Therapeutics, Inc. (ALGS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improvi
6 min readAligos Therapeutics (ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for Pevifoscorvir sodium for chronic HBV. The therapy received China’s NMPA Breakthrough Therapy Designation. Aligos may earn up to $420M in milestones plus tiered royalties; Amoytop plans to start China development of ALG-170675 later this year.
3 min readAligos Therapeutics (ALGS) shares rose about 19.9% in after-hours after the company said it received a $25 million upfront cash payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic HBV. Aligos may receive up to $420 million in milestones plus royalties; the deal extends its cash runway into Q4 2026.
3 min readAligos Therapeutics (Nasdaq: ALGS) said it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China license for pevifoscorvir sodium for chronic hepatitis B. The drug also received China NMPA CDE Breakthrough Therapy Designation, which may enable priority NDA review. Aligos could earn up to $420M in milestones plus royalties; it keeps rights in the US, Europe, Japan, and other markets.
3 min readAligos Therapeutics (NASDAQ:ALGS) shares rose about 21% after hours after it received a $25M upfront payment from Xiamen Amoytop Biotech under an exclusive Greater China licensing deal for pevifoscorvir sodium for chronic hepatitis B. Aligos can earn up to $420M milestones plus royalties; the drug also received China Breakthrough Therapy Designation.
3 min read
